Research programme: nucleic acid therapeutics - Takeda/Wave Life Sciences
Alternative Names: Nucleic acid therapies - Takeda/Wave Life Sciences; Stereopure oligonucleotidesLatest Information Update: 28 Dec 2024
At a glance
- Originator Takeda; WaVe life Sciences
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Nucleic acids; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in CNS-disorders in Japan (Intrathecal)
- 28 Dec 2024 No recent reports of development identified for preclinical development in CNS-disorders in USA (Intrathecal)
- 31 Dec 2023 Wave Life Sciences terminates its collaboration with Takeda with respect to C9 Target and ATXN3 Target